CYT logo

Cyteir Therapeutics, Inc. Common Stock


CYT: Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.


Show CYT Financials

Consumer Interest
SEC Filings

Recent trades of CYT by members of U.S. Congress

Recently reported changes by institutional investors

Quarterly net insider trading by CYT's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of CYT in WallStreetBets Daily Discussion

CYT News

Recent insights relating to CYT

CNBC Recommendations

Recent picks made for CYT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CYT

Corporate Flights

Flights by private jets registered to CYT